Markets took a breather from the November rally - Wednesday Review, December 2

By: Miguel A. Rodriguez

11:19, 03 December 2020

1606985672.jpg
Markets were divided between Pfizer’s vaccine and the rising number of COVID-19 infections

The US

The markets closed mostly higher, boosted by the hopes of a new stimulus package and Pfizer’s potential COVID-19 vaccine. USA30 and USA500 each rose 0.20%. TECH100 lost 0.05%.

Crude oil went up 0.1% to $44.52 per barrel.

Gold traded 0.6% higher at $1,830.20 per ounce.

 

Asia and Australia

The fact that the world could have a viable COVID-19 treatment by the end of the year didn’t faze the Asian and Australian markets. HongKong45 slipped 0.68% after new restrictions were imposed to curb the COVID-19 infections.

Japan225 fell 0.10%.

Down under, Australia200 closed 0.31% lower after the Reserve Bank of Australia announced that it would keep the interest rate unchanged, as expected.

 

Europe

On Wednesday, only the UK’s benchmark UK100 gained 0.1% after it announced that its regulators approved Pfizer and BioNTech’s COVID-19 vaccine for use. The treatment could be distributed as early as next week.

Europe50 was down 0.3%. Germany30 closed 0.4% lower, while France40 fell 0.3%.

Brent Oil lost 0.1% trading at $47.45 a barrel.

EUR/USD closed at 1.2051 after it went down 0.2%.

Sources: investing.com, reuters.com

Share this article

This information prepared by capex.com/za is not an offer or a solicitation for the purpose of purchase or sale of any financial products referred to herein or to enter into any legal relations, nor an advice or a recommendation with respect to such financial products.This information is prepared for general circulation. It does not regard to the specific investment objectives, financial situation, or the particular needs of any recipient.You should independently evaluate each financial product and consider the suitability of such a financial product, by taking into account your specific investment objectives, financial situation, or particular needs, and by consulting an independent financial adviser as needed, before dealing in any financial products mentioned in this document.This information may not be published, circulated, reproduced, or distributed in whole or in part to any other person without the Company’s prior written consent.
Past performance is not always indicative of likely or future performance. Any views or opinions presented are solely those of the author and do not necessarily represent those of capex.com/zaJME Financial Services (Pty) Ltd trading as CAPEX.COM/ZA acts as intermediary between the investor and Magnasale Trading Ltd, the counterparty to the contract for difference purchased by the Investor via CAPEX.COM/ZA, authorised & regulated by the Cyprus Securities and Exchange Commission with license number 264/15.  Magnasale Trading Ltd is the principal to the CFD purchased by investors.